A Phase II Toxicity Study Using Chemotherapy Followed By Intensity Modulated Radiation Therapy to the Pleura in Patients with Locally Advanced Unresectable Malignant Pleural Mesothelioma

Protocol
08-053
Full Title
Phase II Toxicity Study Using Chemotherapy +/- Pleurectomy/Decortication Followed By Intensity Modulated Radiation Therapy to the Pleura in Patients with Locally Advanced Malignant Pleural Mesothelioma
Phase
II
Purpose

The standard treatment for pleural mesothelioma is chemotherapy. Radiation therapy is typically not used because radiation to the lining of the lung has many side effects that are often severe, including damage to the lung (pneumonitis).

Intensity modulated radiation therapy (IMRT), a highly targeted way of delivering radiation, has been shown to cause fewer side effects than standard radiation therapy. IMRT specifically targets the lining of the lung, reducing the risk of damaging the lung itself.

The purpose of this study is to assess the safety of standard chemotherapy followed by IMRT in patients with previously untreated malignant pleural mesothelioma. This treatment approach is not intended as a cure for this cancer, but could potentially keep the tumor under control longer than standard chemotherapy alone.

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have locally advanced pleural mesothelioma that cannot be surgically removed.
  • Patients may not have had prior chemotherapy or radiation therapy.
  • Patients must be age 18 or older.

For more information and to inquire about eligibility for this study, please contact Dr. Lee M. Krug at 646-888-4201.

Disease(s)
Mesothelioma
Related Diseases